Celsion receives NIH SBIR grant to develop heat sensitive liposomal technology for cancer treatment
Celsion receives NIH SBIR grant to develop heat sensitive liposomal technology for cancer treatment
Celsion Corporation, a biotechnology drug development company, announced today that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, “New Thermal Sensitive Carboplatin Liposomes for Cancer”.
Read more on News-Medical-Net